Cargando…
LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial
OBJECTIVES: This report from the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial describes baseline lipase and amylase activity in type 2 diabetic subjects without acute pancreatitis symptoms before randomization to the glucagonlike peptide anal...
Autores principales: | Steinberg, William M., Nauck, Michael A., Zinman, Bernard, Daniels, Gilbert H., Bergenstal, Richard M., Mann, Johannes F.E., Steen Ravn, Lasse, Moses, Alan C., Stockner, Mette, Baeres, Florian M.M., Marso, Steven P., Buse, John B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206347/ https://www.ncbi.nlm.nih.gov/pubmed/25275271 http://dx.doi.org/10.1097/MPA.0000000000000229 |
Ejemplares similares
-
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
por: Daniels, G H, et al.
Publicado: (2015) -
LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ
por: Rutten, Guy E. H. M., et al.
Publicado: (2016) -
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial
por: Petrie, John R., et al.
Publicado: (2016) -
Liraglutide and Glycaemic Outcomes in the LEADER Trial
por: Zinman, Bernard, et al.
Publicado: (2018) -
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial
por: Masmiquel, L., et al.
Publicado: (2016)